DATA GRAPHICS | Data Byte
May decisions also include CStone’s PD-1 inhibitor and Pfizer’s Factor IX gene therapy
By Gunjan Ohri, Data Content Analyst
June 1, 2024 1:03 AM UTC
EMA’s CHMP recommended approval of seven new medicines and label expansions for six, including new indications for Dupixent and Skyrizi.
In May’s review meeting, the committee issued a positive opinion on approval of Dupixent dupilumab from Sanofi (Euronext:SAN; NASDAQ:SNY) as an add-on therapy for chronic obstructive pulmonary disease, a large indication that would help scale Dupixent’s sales, a priority of Sanofi CEO Paul Hudson. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652582/ema-s-chmp-recommends-new-indications-for-dupixent-skyrizi